NCT05064020View on ClinicalTrials.gov

Bictegravir in the Elderly Living With HIV (BICEP)

Active, not recruitingOBSERVATIONAL

Enrollment

162

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

HIV-1-infection

Interventions

DRUG

Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]

Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.

Trial Locations (1)

14201

Evergreen Health, Buffalo

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

State University of New York at Buffalo

OTHER